2020 American Transplant Congress
Utility of Bimonthly Viral Monitoring for Late-Onset Cytomegalovirus Infections in Kidney Transplant Recipients
*Purpose: Kidney transplant recipients with high-risk cytomegalovirus (CMV) serostatus are at risk for late onset CMV after cessation of antiviral prophylaxis.1-2 Evidence for post-prophylactic viral…2020 American Transplant Congress
Absolute Lymphocyte Count: Is There a “Safety Corridor?”
*Purpose: Iatrogenic suppression of T cells is intended to prevent rejection after solid organ transplantation (SOT). This is complicated by opportunistic infections, most notably cytomegalovirus…2020 American Transplant Congress
Effectiveness of Preemptive Therapy in the Prevention of Cytomegalovirus (CMV) Disease in High-Risk (Donor Seropositive/Recipient Seronegative) Liver Transplant Recipients
Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH
*Purpose: Guidelines recommend preemptive therapy (PET) as one strategy for prevention of CMV disease in high risk liver transplant recipients (LTR). However, questions have been…2020 American Transplant Congress
Epidemiology of Cytomegalovirus (CMV) in Pediatric Solid Organ Transplant Recipients (SOTR) at Texas Children’s Hospital (TCH)
Baylor College of Medicine, Houston, TX
*Purpose: Despite widespread use of prevention strategies, CMV remains a common opportunistic infection in SOTR. Contemporary data regarding CMV in pediatric SOTR is limited. We…2020 American Transplant Congress
Gene Expression Dynamics Demonstrate Perturbations in Innate and Adaptive Immunity in Kidney Transplantation Patients with Cytomegalovirus Viremia
University of California Los Angeles, Los Angeles, CA
*Purpose: Cytomegalovirus (CMV) viremia and disease continues to cause significant morbidity and mortality in kidney transplant patients with clinical complications including organ rejection and death.…2020 American Transplant Congress
Twice Weekly Valganciclovir for Cytomegalovirus Infection Prophylaxis in Kidney Transplant Recipients with Delayed Graft Function on Hemodialysis
1Infectious Diseases, NYU Langone Health, New York, NY, 2Pharmacy, NYU Langone Health, New York, NY
*Purpose: The incidence of cytomegalovirus (CMV) remains high in the first year following kidney transplantation. Valganciclovir (VGC) is commonly prescribed in the early post-operative period…2020 American Transplant Congress
Letermovir for CMV Prophylaxis and Treatment of Resistant/ Refractory CMV Disease in Solid Organ Transplant Recipients
*Purpose: Letermovir (LMV) is approved for primary cytomegalovirus (CMV) prophylaxis in hematopoietic cell transplant recipients. Current FDA-approved antiviral options are limited to foscarnet and cidofovir…2020 American Transplant Congress
A Prospective Randomized Multicenter Trial (BEST Trial) of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression: Infectious Complications
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal Trial) is a prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based calcineurin inhibitor-free (CNI), early…2020 American Transplant Congress
Safety and Efficacy of Prophylactic Valganciclovir Dosing after Solid Organ Transplant
Loyola University Medical Center, Maywood, IL
*Purpose: At centers where antiviral prophylaxis is used after solid organ transplant, valganciclovir is administered for the prevention of cytomegalovirus (CMV). At Loyola University Medical…2020 American Transplant Congress
Impact and Outcomes of Primary Cytomegalovirus Infection in Seronegative Abdominal Solid Organ Transplant Recipients of Cytomegalovirus Unexposed Donors (D-/R-)
1UWHC, Madison, WI, 2UWMF, Madison, WI
*Purpose: Primary cytomegalovirus infection (CMV) in high risk (D+/R-) abdominal solid organ transplant recipients (aSOTRs) is well described, however there is a paucity of literature…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 33
- Next Page »